Steward Partners Investment Advisory
XLO icon

Steward Partners Investment Advisory’s Xilio Therapeutics XLO Stock Holding History

Steward Partners Investment Advisory’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.84K Buy
+714
New +$5.96K ﹤0.01% 3862
2025
Q2 		– Sell
-1,429
Closed -$14.5K – 4258
2025
Q1 		$14.5K Hold
1,429
– – ﹤0.01% 2937
2024
Q4 		$19.1K Hold
1,429
– – ﹤0.01% 2823
2024
Q3 		$15.8K Buy
+1,429
New +$17.5K ﹤0.01% 2758

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Steward Partners Investment Advisory's XLO Position: Q2 2026 in Review

Steward Partners Investment Advisory opened a new position in Xilio Therapeutics (XLO) in Q2 2026: 714 shares worth $6.84K. The stake represents ﹤0.01% of the portfolio and ranks #3862 among its holdings. This is a return to the name: Steward Partners Investment Advisory previously reported a position in XLO as recently as Q1 2025.

Steward Partners Investment Advisory first reported a position in XLO in Q3 2024 and has held it in 4 quarters since. The position peaked at $19.1K in Q4 2024. 27 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • Steward Partners Investment Advisory held 714 shares of Xilio Therapeutics worth $6.84K as of Q2 2026.
  • Xilio Therapeutics was a new Steward Partners Investment Advisory position in Q2 2026.
  • Xilio Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #3862 holding.
  • Steward Partners Investment Advisory first reported a position in Xilio Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Steward Partners Investment Advisory's Xilio Therapeutics position peaked at $19.1K in Q4 2024.
  • 27 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.